Chief Commercial Officer (Cco)
CurrentAPEX Labs a pharmaceutical company transforming the standard of mental health care with clinically proven psilocybin treatments,Our mission is to develop and commercialize clinically evaluated psilocybin-derived treatments to tackle the most critical unmet need in depression, anxiety, and PTSD among Veterans and the general population. Apex Labs received Health Canada approval of SUMMIT-90, a landmark double-blind, placebo controlled phase 2b study evaluating multiple doses of APEX-90 administered in-clinic with assisted psychotherapy for the treatment of severe depression within diagnosed PTSD. The 160 patient trial approval comes by way of a no objection letter received from Health Canada on April 14th, 2023 and the company aims to begin recruitment Q2 of 2023.APEX also has a micro-dose take home synthetic psilocybin drug asset, APEX-52 optimized for mild-to-moderate depression. The company recently completed a proof-of-concept trial meeting all clinical endpoints with no adverse events, and subsequently received approval for a 294 patient phase 2b study, PATHFINDER-52, the largest of its kind in the world.